<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0"
  xmlns:content="http://purl.org/rss/1.0/modules/content/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:media="http://search.yahoo.com/mrss/"
  xmlns:atom="http://www.w3.org/2005/Atom"
  xmlns:georss="http://www.georss.org/georss">

  <channel>
    <title>
      <![CDATA[  the cedar ledge  ]]>
    </title>
    <link> https://jacobzelko.com </link>
    <description>
      <![CDATA[  Jacob S. Zelko&#39;s personal website  ]]>
    </description>
    <atom:link
      href="https://jacobzelko.com/feed.xml"
      rel="self"
      type="application/rss+xml" />


<item>
  <title>
    <![CDATA[  Could Autism Spectrum Disorders Be A Risk Factor For covid-19?  ]]>
  </title>
  <link> https://jacobzelko.com/07192020034934-asd-risk-factor/index.html </link>
  <guid> https://jacobzelko.com/07192020034934-asd-risk-factor/index.html </guid>
  <description>
    <![CDATA[  Autism Spectrum Disorders as a potential risk factor in COVID-19 outcomes  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Could Autism Spectrum Disorders Be A Risk Factor For covid-19?</h1>
<p><strong>Date:</strong> July 18 2020</p>
<p><strong>Summary:</strong> Autism Spectrum Disorders as a potential risk factor in COVID-19 outcomes</p>
<p><strong>Keywords:</strong> ##bibliography #asd #autism #covid19 ##pandemic #archive</p>
<h1>Bibliography</h1>
<p>M. E. de Sousa Lima, L. C. M. Barros, and G. F. Aragão, &quot;Could Autism Spectrum Disorders be a Risk Factor for COVID-19?,&quot; Med Hypotheses, May 2020, doi: 10.1016/j.mehy.2020.109899.</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>Cytokine Observations in ASD and COVID19</li></ol></li><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<blockquote>
<p><strong>NOTE:</strong> The journal medical hypothesis lacks a standard peer review process, but is often utilized to posit ideas quickly.</p>
</blockquote>
<p><strong>Purpose of paper:</strong> consolidate data to support the hypothesis of ASD being a risk for COVID19 like other risks.</p>
<p>Involves several modifications at the genetic and at the immune level &#40;e.g. increases of inflammatorycytokines and abnormal immune response in several levels&#41;. &#91;1&#93; Some are conditions considered risk-factor of symptomatic COVID-19 and its mortality.</p>
<h3 id="cytokine_observations_in_asd_and_covid19">Cytokine Observations in ASD and COVID19</h3>
<p>Initially there is an endogenous immune response in the presence of COVID19. The response is linked to the destruction level of the virus, the patient’s innateresponse, and it determines its inflammation status and symptomatology. &#91;2&#93;</p>
<p>Secretory increases of ACE-2 was correlated with COVID-19 patients &#91;3&#93;. There seem to exist an ACE-2 superexpression leading to a pro-inflammatory state, related to cardiac and pulmonary damage &#91;3&#93; ACE-2 is a regulator in angiotensin-2transformation into angiotensin-&#40;1-7&#41; metabolite. It has inflammatory effects producing vasodilatation, anti-proliferation and apoptosis. This is common to CVD conditions &#91;4&#93;.</p>
<p>Coronavirus also has the characteristic of being neuroinvasive. &#91;5&#93; This characteristic shows via:- Febrile seizures - Encephalitis - Convulsions - Change in mental status Some neurological symptomsfound in COVID-19 patients are non-specific, such as headache, dizziness and confusion. Neurological symptoms were directly related to patients. &#91;6&#93; Thereby, we can hypothesize that its physiopathology might have a strict relation with the nervous system.</p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Could Autism Spectrum Disorders Be A Risk Factor For covid-19?</em>. <a href="https://jacobzelko.com/07192020034934-asd-risk-factor">https://jacobzelko.com/07192020034934-asd-risk-factor</a>. July 18 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; H. Ormstad, V. Bryn, O. D. Saugstad, O. Skjeldal, and M. Maes, “Role of the immune system in autism spectrum disorders &#40;ASD&#41;,” CNS Neurol. Disord.-Drug Targets Former. Curr. Drug Targets-CNS Neurol. Disord., vol. 17, no. 7, pp. 489–495, 2018.</p>
<p>&#91;2&#93; Y. Shi et al., “COVID-19 infection: The perspectives on immune responses,” 2020.</p>
<p>&#91;3&#93; Y.-Y. Zheng, Y.-T. Ma, J.-Y. Zhang, and X. Xie, “COVID-19 and the cardiovascular system,” Nat. Rev. Cardiol., vol. 17, no. 5, pp. 259–260, 2020.</p>
<p>&#91;4&#93; A. J. Turner, J. A. Hiscox, and N. M. Hooper, “ACE2: From vasopeptidase to SARS virus receptor,” Trends Pharmacol. Sci., vol. 25, no. 6, pp. 291–294, 2004.</p>
<p>&#91;5&#93; A. A. Asadi-Pooya and L. Simani, “Central nervous system manifestations of COVID-19: A systematic review,” J. Neurol. Sci., p. 116832, 2020.</p>
<p>&#91;6&#93; G. Conde, L. D. Q. Pájaro, I. D. Q. Marzola, Y. R. Villegas, and L. R. M. Salazar, “Neurotropism of SARS-CoV 2: Mechanisms and manifestations,” J. Neurol. Sci., 2020.</p>
<h2 id="discussion">Discussion: </h2>
<script>talkyardServerUrl='https://site-vbm8wbc57o.talkyard.net';</script>
<script async defer src="https://c1.ty-cdn.net/-/talkyard-comments.min.js"></script>
<div class="talkyard-comments" data-discussion-id="" style="margin-top: 45px;">
    <noscript>Please enable Javascript to view comments.</noscript>
    <p style="margin-top: 25px; opacity: 0.9; font-size: 96%">Comments powered by
    <a href="https://www.talkyard.io">Talkyard</a>.</p>
</div> ]]>
  </content:encoded>
    
  <pubDate>Sat, 18 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD  ]]>
  </title>
  <link> https://jacobzelko.com/07102020174816-cytokine-asd-covid19/index.html </link>
  <guid> https://jacobzelko.com/07102020174816-cytokine-asd-covid19/index.html </guid>
  <description>
    <![CDATA[  Loose hypothesis on worsening of cytokine regulation via ASD and COVID19  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD</h1>
<p><strong>Date:</strong> July 10 2020</p>
<p><strong>Summary:</strong> Loose hypothesis on worsening of cytokine regulation via ASD and COVID19</p>
<p><strong>Keywords:</strong> ##zettel #asd #autism ##hypothesis #health #mentalhealth #cytokine ##pandemic #covid19 #archive</p>
<h1>Bibliography</h1>
<p>Not Available</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<blockquote>
<p><strong>Note:</strong> Be careful about conflating correlation with causation.</p>
</blockquote>
<p>I have been closely examining the Hypothalamus Pituitary &#40;HPA&#41; axis and have seen how cytokines directly interact with it. &#91;1&#93; Therefore, since ASD has been correlated with cytokine dysregulation &#91;2&#93;, it can be reasonable to suspect that as coronavirae can also impact cytokine regulation &#91;3&#93;, ASD is a risk factor for COVID19 causing direct problems with the HPA axis leading to multiple downstream issues.</p>
<p>ASD has been correlated with abnormal immune function. This includes:</p>
<ol>
<li><p>Cytokine dysregulation</p>
</li>
<li><p>Inflammation</p>
</li>
<li><p>Presence of autoantibodies</p>
</li>
</ol>
<p>Studies show the presence of anti-brain immunoglobulins in ASD patients. &#91;4&#93; ASD status could also be directly correlated with patients’ cytokine and chemokine levels which cause organ inflammation &#91;2&#93;</p>
<p>There is a second phase resulting in a cytokine storm which particularly affects respiratory epithelium &#91;5&#93;. The storm activates cytokines IL-1-beta, IL-6 and TNFalfa. These activations aggravate respiratory symptoms. These cytokines cause damage to pulmonary microvasculature. It simultaneously affects apoptosis and chemotaxis resulting in decreases of epithelial barriers and alveolar edema <em>Back up references about cytokines</em></p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD</em>. <a href="https://jacobzelko.com/07102020174816-cytokine-asd-covid19">https://jacobzelko.com/07102020174816-cytokine-asd-covid19</a>. July 10 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; M. Marmot and R. Wilkinson, Social Determinants of Health, 2nd ed. Oxford University Press, 2006.</p>
<p>&#91;2&#93; A. M. Depino, “Peripheral and central inflammation in autism spectrum disorders,” Mol. Cell. Neurosci., vol. 53, pp. 69–76, 2013.</p>
<p>&#91;3&#93; S. N. J. Korsman, G. U. van Zyl, L. Nutt, M. I. Andersson, and W. Preiser, “Human coronaviruses,” in Virology, Elsevier, 2012, pp. 94–95.</p>
<p>&#91;4&#93; A. Meltzer and J. Van de Water, “The role of the immune system in autism spectrum disorder,” Neuropsychopharmacology, vol. 42, no. 1, pp. 284–298, 2017.</p>
<p>&#91;5&#93; Q. Ye, B. Wang, and J. Mao, “Cytokine storm in COVID-19 and treatment,” J. Infect., 2020.</p>
<h2 id="discussion">Discussion: </h2>
<script>talkyardServerUrl='https://site-vbm8wbc57o.talkyard.net';</script>
<script async defer src="https://c1.ty-cdn.net/-/talkyard-comments.min.js"></script>
<div class="talkyard-comments" data-discussion-id="" style="margin-top: 45px;">
    <noscript>Please enable Javascript to view comments.</noscript>
    <p style="margin-top: 25px; opacity: 0.9; font-size: 96%">Comments powered by
    <a href="https://www.talkyard.io">Talkyard</a>.</p>
</div> ]]>
  </content:encoded>
    
  <pubDate>Fri, 10 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  Simple, Transparent, and Flexible Automated Quality Assessment Procedures for Ambulatory Electrodermal Activity  ]]>
  </title>
  <link> https://jacobzelko.com/04092020195141-transparent-eda-data/index.html </link>
  <guid> https://jacobzelko.com/04092020195141-transparent-eda-data/index.html </guid>
  <description>
    <![CDATA[  A simple, transparent, flexible, and automated quality assessment procedure for ambulatory EDA data  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Simple, Transparent, and Flexible Automated Quality Assessment Procedures for Ambulatory Electrodermal Activity</h1>
<p><strong>Date:</strong> April 9 2020</p>
<p><strong>Summary:</strong> A simple, transparent, flexible, and automated quality assessment procedure for ambulatory EDA data</p>
<p><strong>Keywords:</strong> ##bibliography #eda #rochester #eda #rules #simple #transparent #autism #children #pediatrics #archive</p>
<h1>Bibliography</h1>
<p>I. R. Kleckner et al., &quot;Simple, Transparent, and Flexible Automated Quality Assessment Procedures for Ambulatory Electrodermal Activity Data,&quot; IEEE Trans. Biomed. Eng., vol. 65, no. 7, pp. 1460–1467, Jul. 2018, doi: 10.1109/TBME.2017.2758643.</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>Rule-based Algorithm<ol><li>Notes on Algorithm Rules</li></ol></li><li>Misc Notes</li></ol></li><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<h3 id="rule-based_algorithm">Rule-based Algorithm</h3>
<p>The authors also decided to create a very simple rule-based algorithm in an effort to make results easily reproducible and understandable to researchers of differing backgrounds. This algorithm for assessing data quality was as is follows:</p>
<table><tr><th align="center">Number</th><th align="center">Rule</th><th align="center">Rationale</th></tr><tr><td align="center">1</td><td align="center">EDA is not within the range of \(0.05 - 60 \mu S\)</td><td align="center">Prevent &quot;floor&quot; and &quot;ceiling&quot; artifacts</td></tr><tr><td align="center">2</td><td align="center">EDA fluctuates too fast \((+/- 10 \frac{\mu S}{second})\)</td><td align="center">To prevent &quot;jump&quot; artifacts</td></tr><tr><td align="center">3</td><td align="center">Temperature not within 30-40 \(C\)</td><td align="center">Preserve best accuracy of data</td></tr><tr><td align="center">4</td><td align="center">EDA data within \(5\) sec of invalid sections</td><td align="center">Invalid sections based on rules \(1-3\)</td></tr></table>
<p>If the data did not adhere to these rules, it was classified as artifact. </p>
<h4 id="notes_on_algorithm_rules">Notes on Algorithm Rules</h4>
<p><em>1. In Rule 1, 60 was chosen as an upper limit specifically because that was the upper limit of the Q Sensor.</em></p>
<p><em>2. Rule 2&#39;s rationale came from &#91;1&#93;–&#91;3&#93;</em></p>
<p><em>3. For Rule 3, their data recorded temperatures of 32 - 36 \(C\) consistently for individuals</em></p>
<h3 id="misc_notes">Misc Notes</h3>
<ul>
<li><p>When collecting EDA data, the authors used solid conductive adhesive hydrogel Ag/AgCl electrodes &#40;22 mm square; model A10040-5 from Vermed; Buffalo, NY&#41;.</p>
</li>
<li><p>Used 181 hours worth of data collected from children and adolescents with autism in an at-home environment.</p>
</li>
</ul>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Simple, Transparent, and Flexible Automated Quality Assessment Procedures for Ambulatory Electrodermal Activity</em>. <a href="https://jacobzelko.com/04092020195141-transparent-eda-data">https://jacobzelko.com/04092020195141-transparent-eda-data</a>. April 9 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; W. Boucsein, Electrodermal Activity. Boston, MA: Springer US, 2012.</p>
<p>&#91;2&#93; R. Kocielnik, N. Sidorova, F. M. Maggi, M. Ouwerkerk, and J. H. Westerink, “Smart technologies for long-term stress monitoring at work,” in Proceedings of the 26th IEEE international symposium on computer-based medical systems, 2013, pp. 53–58.</p>
<p>&#91;3&#93; F. H. Wilhelm and W. T. Roth, “Ambulatory assessment of clinical anxiety,” Ambul. Assess. Comput.-Assist. Psychol. Psychophysiological Methods Monit. Field Stud., pp. 317–345, 1996.</p>
<h2 id="discussion">Discussion: </h2>
<script>talkyardServerUrl='https://site-vbm8wbc57o.talkyard.net';</script>
<script async defer src="https://c1.ty-cdn.net/-/talkyard-comments.min.js"></script>
<div class="talkyard-comments" data-discussion-id="" style="margin-top: 45px;">
    <noscript>Please enable Javascript to view comments.</noscript>
    <p style="margin-top: 25px; opacity: 0.9; font-size: 96%">Comments powered by
    <a href="https://www.talkyard.io">Talkyard</a>.</p>
</div> ]]>
  </content:encoded>
    
  <pubDate>Thu, 09 Apr 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>
</channel></rss>